2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphomas, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

1262 Real-world effectiveness and safety of hetrombopag in patients with newly diagnosed and persistent primary immune thrombocytopenia: A multicenter retrospective study in China

Sun Ting, PhD, Lei Zhang, MD2, Chen Yunfei, MD3, Yanmei Xu4, Renchi Yang5, Chunling Wang6, Kankan Chen7, Xiaojing Hu8, Yirong Jiang, MD9, Yanping Song10, Guang Li11, Huifang Jiang12, Yuxia Jiang13, Jie Bai14, Huiqin Zhang15
1 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
5 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
6 Huai'an First People's Hospital, Huai'an, China
7 Huai'an First People's Hospital, Huai'an, China
8 Dongguan People's Hospital, Dongguan, China
9 Dongguan People's Hospital, Dongguan, China
10 Xi’an Center Hospital, Xi’an, China
11 Xi’an Center Hospital, Xi’an, China
12 Tongde Hospital of Zhejiang Province, Hangzhou, China
13 Tongde Hospital of Zhejiang Province, Hangzhou, China
14 The Second Hospital of Tianjin Medical University, Tianjin, China
15 The Second Hospital of Tianjin Medical University, Tianjin, China

Introduction

Primary immune thrombocytopenia (ITP) is classified by disease duration into newly diagnosed ITP (<3 months), persistent ITP (3-12 months), and chronic ITP (>12 months). Thrombopoietin receptor agonists (TPO-RAs) have been recommended as important subsequent treatment options for ITP. Hetrombopag, an oral TPO-RA currently approved for adult patients with chronic ITP, has limited clinical data regarding its efficacy and safety in newly diagnosed and persistent ITP. This study evaluated the effectiveness and safety of hetrombopag in Chinese patients with newly diagnosed and persistent primary ITP in a real-world setting, aiming to provide additional insights into its application in early-stage ITP.

Methods

This multicenter, retrospective observational study (NCT07268898) enrolled patients aged ≥6 years with clinically diagnosed newly diagnosed or persistent ITP (disease duration ≤12 months) who received subsequent hetrombopag-based therapy between July 2021 and September 2025. Eligible patients had a baseline platelet count (PLT) <30×10?/L, regardless of prior ITP treatment. The primary endpoint was the proportion of patients who achieved, at least once within 8 weeks after treatment initiation, a PLT ≥30×10?/L with at least a 2-fold increase from baseline and no bleeding symptoms. The secondary endpoint was safety. A matching-adjusted indirect comparison (MAIC) was performed using harmonized efficacy endpoint to compare outcomes with the hetrombopag-treated population from a phase III registration trial in adults ITP (NCT03222843).

Results

Among 318 patients screened for subsequent treatment, 236 received TPO-RA–containing regimens, including 94 patients treated with hetrombopag-based regimens who were included in the present analysis. The median age was 50.5 years (range, 11–94), including 68.1% with newly diagnosed ITP and 31.9% with persistent ITP. The median baseline PLT was 8.0×10?/L, and 52.1% of patients had bleeding symptoms at baseline. Hetrombopag-based regimens included monotherapy (4.3%), combination with corticosteroids (74.5%), and combination with non-corticosteroid therapies (21.3%). Within 8 weeks after treatment initiation, 75.5% of patients achieved at least once PLT ≥30×10?/L with at least a 2-fold increase from baseline and no bleeding symptoms. The complete response (CR, defined as at least once PLT ≥100×10?/L without bleeding symptoms) rate was 42.6%. Treatment-emergent adverse events (TEAEs) occurred in 12.8% of patients, including one grade ≥3 TEAE, with no serious TEAEs or fatal adverse events. For the MAIC analysis, response was defined as achieving at least once PLT ≥30×10?/L with at least a 2-fold increase from baseline within 8 weeks after treatment initiation. After weighting, baseline characteristics were well balanced between cohorts. The weighted response rate was 78.5% in the real-world cohort versus 89.1% in the hetrombopag-treated population from the phase III registration trial, with overlapping 95% confidence intervals, indicating consistent efficacy between the two cohorts.

Conclusions

Hetrombopag-based therapy showed favorable effectiveness and safety in Chinese patients with newly diagnosed and persistent ITP in a real-world setting. These findings further inform the use of hetrombopag in early-stage ITP and expand the evidence base beyond chronic ITP.

Sun Ting, PhD: No relevant conflicts of interest to declare.